Details for Patent: 10,669,546

Which drugs does patent 10,669,546 protect, and when does it expire?

Patent 10,669,546 protects QALSODY and is included in one NDA.

This patent has seventy-three patent family members in thirty countries.

Summary for Patent: 10,669,546

Title:	Compositions for modulating SOD-1 expression
Abstract:	Disclosed herein are antisense compounds and methods for decreasing SOD-1 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate SOD-1 associated diseases, disorders, and conditions. Such SOD-1 associated diseases include amyotrophic sclerosis (ALS).
Inventor(s):	Eric E. Swayze
Assignee:	Biogen MA Inc
Application Number:	US16/513,297
Patent Claim Types: see list of patent claims	Use;

US Patent 10,669,546: Scope, Claims, Expiration, and Patent Landscape for Tofersen and Qalsody

US Patent No. 10,669,546 protects human treatment and SOD1-expression-reduction methods using a specifically modified 20-nucleotide antisense oligonucleotide corresponding to tofersen, also known as BIIB067 and IONIS-SOD1Rx. The patent does not claim a broad class of SOD1 antisense compounds, a formulation, a manufacturing process, or intrathecal delivery as an independent invention. Its enforceable center is the use of the specified sequence and chemical modification pattern in human SOD1-associated disease, particularly SOD1-associated amyotrophic lateral sclerosis, or ALS.

The patent was issued on June 2, 2020, and is associated with Ionis Pharmaceuticals’ SOD1 antisense program. Tofersen was later developed and commercialized by Biogen as Qalsody. FDA approved Qalsody on April 25, 2023, under accelerated approval for adults with SOD1 mutation-associated ALS. [1,2]

What drug does US Patent 10,669,546 protect?

The patent protects methods using the tofersen antisense compound, including its pharmaceutically acceptable salts. The disclosed sequence is:

5′-mCAGGATAmCATTTmCATmCAGmCT-3′

The sequence contains 20 nucleobases and is directed against SOD1 messenger RNA. Its chemical architecture is a constrained phosphorothioate gapmer:

Component	Claimed structure
Length	20 nucleotides
Target	Human SOD1 expression
Nucleobases	Adenine, guanine, thymine and 5-methylcytosine
Central gap	2′-deoxyribose residues
Flanking wings	2′-O-methoxyethyl, or MOE, residues
Backbone	Predominantly phosphorothioate
Additional linkages	Phosphodiester linkages at specified positions
Salt form	Pharmaceutically acceptable salts, expressly including sodium salt
Administration	Intrathecal administration is claimed in dependent claims
Clinical product	Tofersen, marketed as Qalsody

The supplied claim language identifies the modification pattern as:

mCes Aeo Ges Geo Aes Tds Ads mCds Ads Tds Tds Tds mCds Tds Ads mCeo Aes Geo mCes Te

Here, e denotes a 2′-O-methoxyethyl sugar, d denotes a 2′-deoxyribose sugar, s denotes a phosphorothioate linkage, and o denotes a phosphodiester linkage.

What are the independent claims in US Patent 10,669,546?

The patent has four substantive independent claims in the supplied claim set: claims 1, 7, 13 and 14.

Claim	Independent subject matter	Main legal limitation
1	Treating or preventing SOD1-associated neurodegenerative disease	Administration of the specifically identified modified antisense sequence
7	Treating or preventing SOD1-associated neurodegenerative disease	Administration of the compound depicted in the structural formula
13	Reducing SOD1 expression	Administration of the specifically identified modified antisense sequence
14	Reducing SOD1 expression	Administration of the compound depicted in the structural formula

Claims 2 through 6 depend from claim 1. Claims 8 through 12 depend from claim 7. Claims 15 through 19 depend from claim 13, while claims 20 through 24 depend from claim 14. Claims 25 and 26 further specify treatment of SOD1-associated ALS under claim 1. Claims 27 and 28 do the same under claim 7.

The text supplied for claims 7 and 14 does not include the referenced chemical structure. That omission prevents a precise comparison between the structural-formula claims and the sequence-defined claims. Their apparent function is to claim the same antisense compound through a chemical structure rather than through a sequence and modification string.

How broad is the scope of the patent claims?

The claims are narrow in chemical identity but potentially meaningful in commercial application.

Chemical scope

Claims 1 and 13 are sequence-specific. A competing antisense compound with a different nucleobase sequence would fall outside those claims unless the structural claims or another patent family independently covered it.

The claims also require the specified sugar and backbone architecture. A compound with the same nucleobase sequence but a materially different modification pattern could avoid literal infringement. Examples include:

• A fully phosphorothioate backbone if the claimed pattern requires phosphodiester linkages at specific positions.
• A locked nucleic acid or constrained ethyl modification instead of MOE.
• A different wing-gap arrangement.
• A different methylation pattern.
• A different stereochemical configuration of phosphorothioate linkages, depending on claim construction and prosecution history.
• A different salt or conjugated form, if it is not a pharmaceutically acceptable salt of the claimed compound.

The claims do not appear to cover all SOD1-targeting oligonucleotides, all gapmer designs, or all antisense compounds that reduce SOD1 expression.

Therapeutic scope

The independent treatment claims cover:

1. Treatment or prevention of an SOD1-associated neurodegenerative disorder.
2. Administration to a human subject.
3. A therapeutically effective amount.
4. The claimed antisense compound or its pharmaceutically acceptable salt.

The dependent claims identify SOD1-associated ALS. This provides a direct claim position against commercial use of tofersen in the approved indication.

Delivery scope

Intrathecal administration is not required by independent claims 1, 7, 13 or 14. It is added by dependent claims 3, 6, 9, 12, 16, 19, 21, 24, 26 and 28.

This structure gives the patent two enforcement positions:

• A broader method claim that does not expressly require intrathecal delivery.
• A narrower but commercially aligned claim that expressly covers intrathecal administration.

Qalsody is administered by intrathecal bolus injection. [2] The approved route therefore falls squarely within the intrathecal dependent claims.

What does each claim group cover?

Claims 1 through 6: treatment and prevention

Claims 1 through 6 cover administering the identified antisense compound to a human with an SOD1-associated neurodegenerative disorder. Claim 2 specifies SOD1-associated ALS. Claims 3 and 6 specify intrathecal administration. Claim 4 covers a sodium salt.

The term “preventing” potentially reaches administration before clinical manifestation of disease, although actual enforceability would depend on the facts of the treatment protocol and the applicable claim-construction record.

Claims 7 through 12: structural-formula treatment claims

Claims 7 through 12 use a structural representation instead of the fully written sequence and modification notation. These claims are important because they may provide an alternative claim format if a court construes the sequence notation narrowly.

Their precise breadth cannot be determined from the supplied text because the chemical structure referenced in claims 7 and 14 is absent.

Claims 13 through 24: SOD1-expression reduction

Claims 13 and 14 are directed to reducing SOD1 expression rather than expressly treating a disease. Claims 15 and 20 link the method to SOD1-associated ALS, while the remaining dependent claims address intrathecal administration, sodium salt, and therapeutic administration.

These claims could be relevant to uses in clinical trials, biomarker-directed treatment, or research protocols in which reduction of SOD1 expression is the stated objective. They may also provide a different infringement theory from disease-treatment claims, particularly where a product label or protocol emphasizes molecular reduction rather than treatment of ALS.

Claims 25 through 28: ALS treatment

Claims 25 through 28 are the most commercially direct claims for Qalsody. They expressly require treatment of SOD1-associated ALS and, in claims 26 and 28, intrathecal administration.

They are narrower than claims 1 and 7 because they specify the disease and, for the final dependent claims, the route. Their value is practical: the approved Qalsody use appears to satisfy these limitations.

When does US Patent 10,669,546 lose exclusivity?

The listed patent expiration date is March 14, 2034. [3] The effective expiration date should be assessed against the official patent record, including any patent term adjustment, terminal disclaimer, patent term extension, or later correction.

Exclusivity category	Relevant date or period
Patent grant	June 2, 2020
FDA Qalsody approval	April 25, 2023
Orphan-drug exclusivity	Generally through April 25, 2030
Listed US patent expiration	March 14, 2034
Practical earliest broad generic competition	Dependent on ANDA eligibility, patents, exclusivity and litigation

Qalsody received orphan-drug designation and approval for SOD1 mutation-associated ALS. Orphan exclusivity generally blocks FDA approval of the same drug for the same orphan indication for seven years, subject to statutory exceptions. [1,4]

The patent extends beyond the orphan-exclusivity period. This creates a potential period from 2030 to 2034 in which regulatory orphan exclusivity may have ended but the listed method patent remains a major barrier to an ANDA applicant seeking an indication that overlaps the patented use.

What is the Orange Book status of Qalsody?

Qalsody is approved under an NDA rather than a biologics license application. Because tofersen is an antisense oligonucleotide drug, its patents and exclusivity are evaluated through the small-molecule drug framework rather than the biosimilar pathway used for biological products.

US Patent 10,669,546 is associated with the Qalsody patent estate and has been identified with a March 14, 2034 expiration date in FDA patent-listing materials. [3] The patent is a method-of-use patent. It does not, based on the supplied claims, claim a tablet, injectable formulation, vial presentation, device, or manufacturing process.

An ANDA applicant would need to address the listed patent through one of the following mechanisms:

• Paragraph III certification, accepting no launch before patent expiration.
• Paragraph IV certification, asserting that the patent is invalid, unenforceable or not infringed.
• A section viii statement carving out a patented indication, if the proposed label can omit the protected use.
• A suitability or other regulatory pathway, if legally available and applicable to the proposed product.

Because the approved product is administered intrathecally for a genetically defined ALS population, a section viii strategy may be commercially difficult if the proposed label still describes SOD1-associated ALS treatment.

What Paragraph IV challenges and patent litigation affect Qalsody?

The supplied claim set does not identify an ANDA filing, Paragraph IV notice, district-court action or settlement agreement. No litigation position can be inferred solely from the patent claims.

The primary litigation issues would likely be:

Issue	Potential defense or challenge
Infringement	Accused product does not contain the claimed sequence or modification pattern
Claim construction	Sequence notation, sugar designation and linkage placement are ambiguous or limited by prosecution history
Written description	The asserted claims may be challenged if the specification does not adequately support the full structural scope
Enablement	The challenger may argue that the claimed therapeutic use is broader than the demonstrated disclosure
Obviousness	Prior SOD1 antisense sequences, gapmer chemistry and ALS data may be combined to challenge patentability
Divided infringement	Method claims require proof that a person administered or directed administration of the compound
Label-based infringement	Liability may depend on the wording of an ANDA label or clinical-use instructions

The narrow compound definition strengthens validity against broad prior-art attacks but gives a generic manufacturer a clearer design-around path. A compound that changes both sequence and chemistry would have a stronger non-infringement position than a product that merely changes the salt form.

Are biosimilar or generic risks different for tofersen?

Generic risk

Qalsody is exposed to conventional generic-drug risk because its approval is under an NDA. An ANDA applicant could attempt to show pharmaceutical equivalence and bioequivalence or seek an alternative approval strategy appropriate to an oligonucleotide drug.

The main barriers are:

• The March 2034 patent expiration.
• The orphan-exclusivity period ending in April 2030.
• Complexity in demonstrating equivalence for an intrathecally administered antisense compound.
• Potential difficulty obtaining a label that avoids the patented SOD1-ALS use.
• Manufacturing controls for sequence identity, impurity profile, chain length distribution and stereochemical composition.

Biosimilar risk

Biosimilar risk is not the principal pathway for tofersen. Qalsody is not regulated as a conventional therapeutic protein biologic. A competitor would more likely pursue an abbreviated drug application or another drug-specific pathway rather than a section 351(k) biosimilar application.

The absence of a biosimilar pathway does not eliminate competition. It changes the regulatory route and may make manufacturing and analytical comparability more important.

How strong is the patent estate for Qalsody?

US Patent 10,669,546 is strong against an exact-copy commercial product but narrower against next-generation SOD1 antisense programs.

Strengths

• It identifies the clinical compound with high chemical specificity.
• It covers the approved disease area through dependent ALS claims.
• It covers intrathecal administration through multiple dependent claims.
• It includes both treatment and SOD1-expression-reduction theories.
• The listed expiration extends beyond the seven-year orphan-exclusivity period.
• The patent can potentially be asserted against an ANDA label that directly seeks SOD1-associated ALS treatment.

Weaknesses

• The principal claims are method claims, not composition claims.
• A non-identical SOD1 antisense compound may avoid literal infringement.
• No formulation or manufacturing claims appear in the supplied claim set.
• The claim set does not expressly recite dose, dosing interval, loading regimen or concentration.
• The dependent intrathecal claims are narrower than the independent claims.
• Validity may turn on the scope of the original disclosure and the state of antisense and SOD1 prior art.

The estate should therefore be viewed as product-specific rather than platform-wide.

What formulations and manufacturing activities are protected?

The supplied claims do not expressly protect:

• A specific vial or concentration.
• A buffer system.
• A preservative-free formulation.
• A syringe or injection device.
• A dosing schedule.
• A manufacturing process.
• A purification process.
• A stereopure phosphorothioate distribution.
• A conjugate for enhanced tissue delivery.

The claims may reach any pharmaceutically acceptable formulation containing the claimed compound when used in the claimed method. That is indirect protection arising from the method claim, not a standalone formulation claim.

Manufacturing remains a practical barrier. An entrant must produce a highly characterized 20-mer antisense oligonucleotide with the required MOE, deoxy, methylcytosine, phosphorothioate and phosphodiester pattern. Regulatory review would also examine identity, purity, residual impurities, aggregation or particulates, sterility and consistency of the finished intrathecal product.

Which companies are challenging the SOD1 antisense market?

The commercial field is concentrated.

Company	Program or product	Strategic position
Biogen	Tofersen, Qalsody	Approved SOD1 ALS therapy
Ionis Pharmaceuticals	Original SOD1 antisense developer	Originator technology and patent contributor
Wave Life Sciences	WVE-006 and related RNA programs	Competing SOD1-directed genetic medicine approach
QurAlis and other ALS developers	SOD1 and genetically defined ALS programs	Earlier-stage competition, depending on program status
Academic and biotechnology groups	SOD1 silencing, editing and replacement approaches	Potential long-term substitutes

Qalsody’s most direct competition is not currently an interchangeable generic. It is competing genetic-medicine development directed at SOD1 suppression, RNA editing, gene silencing or allele-selective treatment.

What generic launch scenarios exist?

Launch before patent expiration

An early launch would require a successful Paragraph IV challenge, settlement permitting an earlier entry date, or a non-infringing label and product design that avoids the listed claims.

Launch after orphan exclusivity but before patent expiration

This is the most important theoretical window. After April 25, 2030, orphan exclusivity may no longer block the same indication, but a listed method patent could still prevent approval or commercial launch unless the applicant uses a successful section viii strategy or defeats the patent.

Launch after March 14, 2034

This is the lowest patent-risk scenario for an exact tofersen copy, subject to any applicable patent-term adjustment, extension, regulatory exclusivity, pediatric exclusivity or additional later-expiring patents.

Key Takeaways

• US Patent 10,669,546 is a product-specific method patent for tofersen, the active ingredient in Qalsody.
• The core sequence is a 20-nucleotide SOD1 antisense gapmer with MOE wings, a deoxy central gap and mixed phosphorothioate/phosphodiester linkages.
• Independent claims cover treatment or prevention of SOD1-associated disease and reduction of SOD1 expression.
• SOD1-associated ALS and intrathecal administration are added through dependent claims.
• The patent does not, based on the supplied claims, independently protect a formulation, dose, device, manufacturing method or broad SOD1 antisense platform.
• The listed patent expiration date is March 14, 2034.
• Qalsody’s orphan-drug exclusivity generally runs through April 25, 2030.
• Generic risk is more relevant than biosimilar risk because Qalsody is approved under an NDA.
• The patent is strong against an exact-copy tofersen product but offers a more limited barrier against chemically or sequence-distinct SOD1 antisense compounds.
• Claims 7 and 14 require the missing structural formula for a complete scope and infringement analysis.

FAQs About US Patent 10,669,546 and Qalsody

Does US Patent 10,669,546 cover all SOD1 ALS drugs?

No. It principally covers methods using the specified tofersen antisense compound or the compound represented by the referenced structural formula. A different SOD1 sequence or materially different chemistry may fall outside its literal scope.

Is intrathecal injection required for infringement?

No. Intrathecal administration is expressly required only by dependent claims. The independent treatment and expression-reduction claims do not expressly require that route.

Can a company develop a different SOD1 antisense drug without infringing this patent?

Potentially. A different sequence, sugar pattern, backbone architecture or chemical form could avoid the claims, but the complete patent family and any related continuation patents would need to be reviewed.

Does the patent cover Qalsody’s dosing schedule?

The supplied claims do not recite a specific dose, concentration, loading schedule or maintenance interval. They require administration of a therapeutically effective amount.

What is the most important missing issue in evaluating claims 7 and 14?

The chemical structures referenced in those claims are absent from the supplied claim text. Without them, the relationship between the structural claims and the sequence-defined claims cannot be determined precisely.

References

1. U.S. Food and Drug Administration. (2023, April 25). FDA approves first drug for patients with amyotrophic lateral sclerosis with a mutation in the SOD1 gene. https://www.fda.gov/

2. Biogen Inc. (2023). Qalsody (tofersen) prescribing information. U.S. Food and Drug Administration.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (n.d.). Orphan drug designations and approvals. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/

Drugs Protected by US Patent 10,669,546

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Biogen Ma	QALSODY	tofersen	SOLUTION;INTRATHECAL	215887-001	Apr 25, 2023		RX	Yes	Yes						TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN ADULTS WHO HAVE A MUTATION IN THE SUPEROXIDE DISMUTASE 1 (SOD1) GENE

International Family Members for US Patent 10,669,546

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	3126499		CR 2024 00038	Denmark
European Patent Office	3126499		301293	Netherlands
European Patent Office	3126499		LUC00359	Luxembourg
European Patent Office	3126499		PA2024531	Lithuania
European Patent Office	3126499		2024C/538	Belgium